Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension

Core Insights - Mineralys Therapeutics Inc. (NASDAQ:MLYS) has received FDA acceptance for its New Drug Application (NDA) for lorundrostat, aimed at treating hypertension in conjunction with other medications [1][2] - The company's CEO highlighted that despite the Explore-OSA trial not demonstrating a reduction in the apnea-hypopnea index (AHI), the drug's safety profile and its effects on blood pressure are significant [1] - Bank of America raised the price target for MLYS shares from $43 to $46, maintaining a Buy rating following the company's Q3 2025 earnings report, which confirmed a cash runway until 2027 [2] Company Overview - Mineralys Therapeutics Inc. is a biotechnology firm focused on developing treatments for conditions related to aldosterone dysregulation, headquartered in Radnor, Pennsylvania [3]